GRAIL, Inc. (GRAL)
79.56
-2.98
(-3.62%)
USD |
NASDAQ |
Aug 26, 16:00
79.56
0.00 (0.00%)
After-Hours: 20:00
GRAIL Shareholders Equity (Quarterly) : 2.543B for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.543B |
| March 31, 2026 | 2.501B |
| December 31, 2025 | 2.578B |
| September 30, 2025 | 2.240B |
| June 30, 2025 | 2.315B |
| March 31, 2025 | 2.414B |
| December 31, 2024 | 2.503B |
| September 30, 2024 | 2.588B |
| June 30, 2024 | 2.695B |
| March 31, 2024 | 3.739B |
| December 31, 2023 | 3.646B |
| September 30, 2023 |
| Date | Value |
|---|---|
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | 609.94M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.48M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.844B |
| Total Liabilities (Quarterly) | 301.03M |
| Debt to Equity Ratio | 0.0359 |
| Current Ratio | 10.95 |
| Net Debt Paydown Yield | -0.18% |